Ginkgo Bioworks Holdings, Inc.
General ticker "DNA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $538.8M (TTM average)
Ginkgo Bioworks Holdings, Inc. follows the US Stock Market performance with the rate: 19.7%.
Estimated limits based on current volatility of 6.9%: low 10.21$, high 11.73$
Factors to consider:
- Total employees count: 485 (-41.8%) as of 2025
- US accounted for 88.0% of revenue in the fiscal year ended 2022-12-31
- Top business risk factors: History of losses, Insufficient capital, Organizational changes, Limited operating history, Economic downturns and volatility
- Price in estimated range
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.81$, 14.87$]
- 2026-12-31 to 2027-12-31 estimated range: [5.01$, 13.15$]
Financial Metrics affecting the DNA estimates:
- Negative: with PPE of -1.5 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Industry operating income (median)
- Negative: negative Net income
- Negative: 42.26 < Shareholder equity ratio, % of 45.42 <= 49.86
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: 1.34 < Inventory ratio change, % of 1.37
- Negative: Investing cash flow per share per price, % of -50.97 <= -40.59
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Negative: negative Industry operating cash flow (median)
Short-term DNA quotes
Long-term DNA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $251.46MM | $227.04MM | $170.16MM |
| Operating Expenses | $1,115.86MM | $786.80MM | $485.43MM |
| Operating Income | $-864.41MM | $-559.76MM | $-315.28MM |
| Non-Operating Income | $-28.53MM | $12.25MM | $1.68MM |
| Interest Expense | $0.09MM | $0.09MM | $0.00MM |
| R&D Expense | $580.62MM | $424.06MM | $243.77MM |
| Income(Loss) | $-892.94MM | $-547.51MM | $-313.60MM |
| Taxes | $-0.07MM | $-0.48MM | $-0.84MM |
| Net Income(Loss)* | $-892.87MM | $-547.03MM | $-312.76MM |
| Stockholders Equity | $1,097.15MM | $716.06MM | $508.59MM |
| Inventory | $0.05MM | $0.00MM | $0.00MM |
| Assets | $1,665.34MM | $1,377.45MM | $1,119.70MM |
| Operating Cash Flow | $-295.50MM | $-319.58MM | $-171.06MM |
| Capital expenditure | $40.80MM | $62.54MM | $7.67MM |
| Investing Cash Flow | $-80.69MM | $-62.24MM | $-240.29MM |
| Financing Cash Flow | $-3.22MM | $-1.74MM | $17.77MM |
| Earnings Per Share** | $-18.40 | $-10.54 | $-5.64 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.